Ascentage Pharma Group International (AAPG) Current Deferred Revenue: 2023-2025
- Ascentage Pharma Group International's Current Deferred Revenue was N/A to $5.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $5.1 million for FY2024, which is 97.96% down from last year.
- Latest data reveals that Ascentage Pharma Group International reported Current Deferred Revenue of $5.2 million as of Q2 2025, which was up 0.92% from $5.1 million recorded in Q4 2024.
- In the past 5 years, Ascentage Pharma Group International's Current Deferred Revenue ranged from a high of $5.3 million in Q4 2023 and a low of $5.1 million during Q4 2024.
- In the last 3 years, Ascentage Pharma Group International's Current Deferred Revenue had a median value of $5.2 million in 2025 and averaged $5.2 million.
- Data for Ascentage Pharma Group International's Current Deferred Revenue shows a maximum YoY dropped of 3.74% (in 2024) over the last 5 years.
- Ascentage Pharma Group International's Current Deferred Revenue (Quarterly) stood at $5.3 million in 2023, then declined by 3.74% to $5.1 million in 2024, then reached $5.2 million in 2025.
- Its Current Deferred Revenue stands at $5.2 million for Q2 2025, versus $5.1 million for Q4 2024 and $5.3 million for Q4 2023.
